SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors digest news of a convertible note repurchase and anticipate major catalysts, including a pending European Medicines Agency (EMA) opinion and the upcoming activation of a permanent J-code for Yartemlea. The community is actively debating the company's long-term valuation, potential milestone payments from Novo Nordisk, and the impact of the recent stock price volatility on the company's debt management strategy.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending due to heightened volatility driven by fresh military escalations between the U.S. and Iran, which are disrupting energy infrastructure and supply chains in the Middle East. Community discussion is sharply divided, with traders debating whether ongoing ceasefire rumors are manipulative tactics to suppress oil prices or if the supply-demand imbalance from record-low reserves will inevitably force prices higher.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh geopolitical risks and supply disruptions in the Middle East against the company's strong long-term expansion plans. The community is actively debating the disconnect between the stock's valuation and the rising global demand for LNG, while keeping a close eye on the upcoming earnings report and potential impacts from regional energy infrastructure conflicts.

Ambarella, Inc. engages in the development of low-power system-on-a-chip (SoC), semiconductors, and software for edge artificial intelligence (AI) applications and intelligent automation. The firm's products include video security, advanced driver assistance (ADAS), electronic mirror, drive recorder, driver or cabin monitoring, autonomous driving, and other robotics applications. It operates through the following geographical segments: Taiwan, Asia Pacific, Europe, North America, and United States. The company was founded by Feng Ming Wang and Leslie D. Kohn on January 15, 2004 and is headquartered in Santa Clara, CA.

Ambarella Inc

Ambarella Inc. is trending as investors digest a potential acquisition by NXP Semiconductors, which would bolster NXP's automotive edge AI and computer vision capabilities. While the stock has seen significant volatility amid the buyout rumors, the community is actively debating whether the company's valuation remains attractive or if the speculative premium has already been priced in.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group Inc. is trending as shares dropped sharply following FDA briefing documents that criticized the clinical trial data for its melanoma drug RP1, citing inflated response rates and design flaws ahead of an upcoming advisory committee meeting. The community is sharply divided, with many debating the impact of the FDA's negative review on approval odds while others discuss the potential for a short squeeze or further downside volatility.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is currently trending as investors focus on its consistent monthly dividend payouts and its role as a core holding in income-focused retirement strategies. Community discussions are actively debating the fund's performance relative to other income ETFs, with many members sharing their accumulation plans and dividend reinvestment strategies to build long-term cash flow.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest the robust phase 3 results for daraxonrasib in pancreatic cancer and speculate on the company's potential as a major M&A target. The community is actively debating the stock's valuation, its platform-wide potential against patent cliffs, and comparisons to other high-profile clinical-stage biotech players.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as investors weigh strong demand for the Wegovy pillhighlighted by recent EU approval and aggressive global rolloutsagainst a legal battle with Eli Lilly over obesity drug advertising. While the stock remains volatile due to pipeline setbacks and competitive pressures, community sentiment is shifting toward long-term bullishness, with many pointing to favorable valuations and the potential for a guidance beat in upcoming financial results.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. The company operates through the OSS and OSS Europe segments. One Stop Systems was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing high community engagement driven by recent defense contract wins and anticipation regarding potential future contracts with the Department of Defense. Investors are primarily focused on the company's strong book-to-bill ratio and rugged edge AI technology, viewing recent price volatility as a healthy consolidation period rather than a breakdown in the long-term growth thesis.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore is currently trending as investors closely monitor pending federal court rulings and the company's progress on critical debt refinancing, which remain the primary drivers of market volatility. The community is actively debating the company's potential to scale production and secure federal support, with sentiment split between those anticipating a major re-rating and those wary of ongoing legal and balance sheet risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jersey Mike's Subs recently completed its high-profile public debut on the NYSE, sparking intense community debate as the stock opened below its initial offering price. Investors are actively split between those betting on the brand's rapid expansion potential and long-term growth and those expressing skepticism over its valuation, debt levels, and the sustainability of premium pricing in the current economic environment.

NYSE Content Update: Jersey Mike's Raises $1 Billion Ahead of NYSE Debut

NYSE Content Update: Jersey Mike's Raises $1 Billion Ahead of NYSE Debut NYSE Content Update: Jersey Mike's Raises $1 Billion Ahead of NYSE Debut PR Newswire NEW YORK, July 30, 2026 NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, July 30, 2026 /PRNewswire/ -- The New...

Jersey Mike's Subs, Inc. engages in franchising fast casual, submarine-style sandwich restaurants specializing in authentic, hand-crafted, and craveable subs. The company was founded by Peter Cancro in 1956 and is headquartered in Tinton Falls, DE.

Jersey Mike`s Subs Inc. - Ordinary Shares - Class A

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$23.00
Prev Close	$21.63
Open	$21.98
Dividend Yield	N/A
50-Day Moving Average	$22.32
Beta	0.00
Avg. Volume	0.00
PE Ratio	N/A

52-Week High	$23.00
52-Week Low	$20.63
Market Capitalization	$5.93B
EPS (Annual)	$0.1732
Price to Book	1.18
Revenue Per Employee	$880,778.59

Feed

News

Sentiment

Fundamentals

Info